The purpose of the study is to describe how well pegcetacoplan works in everyday medical practice and to assess its safety. Participants who are already receiving the medication will be followed for several years, with regular visits at roughly one, three, six, and twelve months after starting treatment and then every six months thereafter. During these visits doctors will check the amount of protein in the urine using a test called UPCR (a measurement of protein‑to‑creatinine ratio) and will evaluate kidney filtering ability with the eGFR test, which estimates how efficiently the kidneys are cleaning the blood. Simple questionnaires may also be used to capture how patients feel and how the disease affects daily life.

In addition to the main health checks, information such as age, sex, other medicines being taken, and any side effects will be recorded. Safety monitoring includes watching for serious infections, significant drops in kidney function, and the need for procedures like dialysis or a kidney transplant. The collected data will help doctors understand the overall benefit‑risk profile of the drug for people living with these rare kidney conditions.

Participants in the study will receive Iptacopan over a period of time, with the maximum treatment period being 66 weeks. The study will monitor how well the medication works in managing the kidney conditions and will also keep track of any side effects or issues that may arise during the treatment. The study aims to provide valuable information on how Iptacopan can help in treating these specific kidney diseases.

Throughout the study, participants will have regular check-ups to assess their kidney function and overall health. This will include monitoring important health indicators and any changes in the condition of the kidneys. The study is designed to ensure that participants are closely observed to gather comprehensive data on the long-term use of Iptacopan for these kidney diseases.

The purpose of the study is to evaluate how effective and safe Pegcetacoplan is for patients with C3G or IC-MPGN. Participants in the study will receive the treatment twice a week. The study will last for a period of time, during which participants will be monitored to see if there is a reduction in proteinuria, which is the presence of excess protein in the urine and a sign of kidney damage. The study aims to see if Pegcetacoplan can help reduce this proteinuria and improve kidney function.

Throughout the study, participants will receive regular check-ups to monitor their health and the effects of the treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results. The study will help determine if Pegcetacoplan can be a beneficial treatment option for those suffering from these specific kidney diseases.

The purpose of the study is to evaluate how effective pegcetacoplan is in improving the health of the kidneys affected by C3G or IC-MPGN. Participants in the study will receive pegcetacoplan through a subcutaneous injection, which means it is administered under the skin. The study will last for a period of 12 weeks, during which the effects of the treatment on the kidney condition will be closely monitored. An ambulatory syringe infusion system, known as the FreedomEdge® Syringe Infusion System, will be used to administer the medication.

Throughout the study, participants will undergo regular check-ups to assess the safety and effectiveness of the treatment. The main goal is to see if there is a reduction in the damage to the kidneys, as indicated by changes in specific markers in the kidney tissue. The study will also monitor other health indicators, such as kidney function and overall safety, to ensure that the treatment is both effective and safe for participants. The trial is open-label, meaning both the participants and the researchers know which treatment is being administered.

The purpose of the study is to evaluate the effectiveness and safety of iptacopan in patients with complement 3 glomerulopathy. Participants in the study will be randomly assigned to receive either iptacopan or a placebo. The study will last for up to 12 months, during which participants will take the medication orally. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

This study involves both adult and adolescent participants. For adults, the main goal is to see if iptacopan is better than a placebo at reducing proteinuria. For adolescents, the study will look at the effect of iptacopan on proteinuria after six months. Participants will be closely monitored for any changes in their kidney function and overall health, ensuring that the treatment is safe and effective.

The purpose of the study is to evaluate how effective and safe aliskiren is in reducing kidney inflammation and improving kidney function compared to enalapril. Participants in the study will receive either aliskiren or enalapril for a period of time, and then switch to the other medication. This approach helps researchers understand the effects of each treatment on the disease.

Throughout the study, participants will have regular check-ups to monitor their kidney function and the levels of certain proteins in their blood. These proteins, like serum C3, are indicators of how well the kidneys are functioning and how the disease is progressing. The study aims to find out if aliskiren can be a better treatment option for people with C3 glomerulopathy compared to the current standard treatment with enalapril.

Participants in this study will receive pegcetacoplan, which is administered as a subcutaneous infusion, meaning it is given under the skin using a special device. The study will monitor participants over time to see how their kidney function changes and to check for any side effects. The study will also compare the results to those from before the treatment started to see if there are improvements in kidney health.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their condition. The study will last for several years, allowing researchers to gather comprehensive data on the long-term effects of pegcetacoplan. This information will help determine if pegcetacoplan is a viable long-term treatment option for these kidney diseases.